Výsledky vyhledávání - Sai‐Hong Ignatius Ou

Upřesnit hledání
  1. 1
    Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged nonsmall cell lung cancer and beyond

    Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged nonsmall cell lung cancer and beyond Autor Sai‐Hong Ignatius Ou

    Vydáno 2011
    Získat plný text Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  2. 2
    Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer

    Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Autor Sai‐Hong Ignatius Ou, Jason A. Zell

    Vydáno 2008
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  3. 3
    Validation Study of the Proposed IASLC Staging Revisions of the T4 and M Non-small Cell Lung Cancer Descriptors Using Data from 23,583 Patients in the California Cancer Registry

    Validation Study of the Proposed IASLC Staging Revisions of the T4 and M Non-small Cell Lung Cancer Descriptors Using Data from 23,583 Patients in the California Cancer Registry Autor Sai‐Hong Ignatius Ou, Jason A. Zell

    Vydáno 2008
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  4. 4
    Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies

    Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Autor Sai‐Hong Ignatius Ou, Jason A. Zell

    Vydáno 2009
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  5. 5
    The Applicability of the Proposed IASLC Staging Revisions to Small Cell Lung Cancer (SCLC) with Comparison to the Current UICC 6th TNM Edition

    The Applicability of the Proposed IASLC Staging Revisions to Small Cell Lung Cancer (SCLC) with Comparison to the Current UICC 6th TNM Edition Autor Sai‐Hong Ignatius Ou, Jason A. Zell

    Vydáno 2009
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  6. 6
    Catalog of 5′ fusion partners in RET+ NSCLC Circa 2020

    Catalog of 5′ fusion partners in RET+ NSCLC Circa 2020 Autor Sai‐Hong Ignatius Ou, Viola W. Zhu

    Vydáno 2020
    Získat plný text Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  7. 7
    Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno

    Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno Autor Danielle Brazel, Sai‐Hong Ignatius Ou, Misako Nagasaka

    Vydáno 2023
    Získat plný text Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  8. 8
    Taletrectinib for the treatment of <i>ROS-1</i> positive non-small cell lung cancer: a drug evaluation of phase I and II data

    Taletrectinib for the treatment of <i>ROS-1</i> positive non-small cell lung cancer: a drug evaluation of phase I and II data Autor Misako Nagasaka, Danielle Brazel, Sai‐Hong Ignatius Ou

    Vydáno 2024
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  9. 9
    Asian Ethnicity Is a Favorable Prognostic Factor for Overall Survival in Non-small Cell Lung Cancer (NSCLC) and Is Independent of Smoking Status

    Asian Ethnicity Is a Favorable Prognostic Factor for Overall Survival in Non-small Cell Lung Cancer (NSCLC) and Is Independent of Smoking Status Autor Sai‐Hong Ignatius Ou, Argyrios Ziogas, Jason A. Zell

    Vydáno 2009
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  10. 10
    Prognostic Factors for Survival in Extensive Stage Small Cell Lung Cancer (ED-SCLC): The Importance of Smoking History, Socioeconomic and Marital Statuses, and Ethnicity

    Prognostic Factors for Survival in Extensive Stage Small Cell Lung Cancer (ED-SCLC): The Importance of Smoking History, Socioeconomic and Marital Statuses, and Ethnicity Autor Sai‐Hong Ignatius Ou, Argyrios Ziogas, Jason A. Zell

    Vydáno 2009
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  11. 11
    Liquid Biopsy to Identify Actionable Genomic Alterations

    Liquid Biopsy to Identify Actionable Genomic Alterations Autor Sai‐Hong Ignatius Ou, Misako Nagasaka, Viola W. Zhu

    Vydáno 2018
    Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  12. 12
    Catalog of 5’ Fusion Partners in ALK-positive NSCLC Circa 2020

    Catalog of 5’ Fusion Partners in ALK-positive NSCLC Circa 2020 Autor Sai‐Hong Ignatius Ou, Viola W. Zhu, Misako Nagasaka

    Vydáno 2020
    Získat plný text Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  13. 13
    From preclinical efficacy to 2022 (36.7 months median follow -up) updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK+ NSCLC

    From preclinical efficacy to 2022 (36.7 months median follow -up) updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK+ NSCLC Autor Sai‐Hong Ignatius Ou, Alexandria TM Lee, Misako Nagasaka

    Vydáno 2023
    Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  14. 14
    Comprehensive Survey of AACR GENIE Database of Tumor Mutation Burden (TMB) Among All Three Classes (I, II, III) of BRAF Mutated (BRAF+) NSCLC

    Comprehensive Survey of AACR GENIE Database of Tumor Mutation Burden (TMB) Among All Three Classes (I, II, III) of BRAF Mutated (BRAF+) NSCLC Autor Zhaohui Arter, Kevin Shieh, Misako Nagasaka, Sai‐Hong Ignatius Ou

    Vydáno 2025
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  15. 15
    Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

    Targeting MET in Lung Cancer: Will Expectations Finally Be MET? Autor Alexander Drilon, Federico Cappuzzo, Sai‐Hong Ignatius Ou, D. Ross Camidge

    Vydáno 2016
    Získat plný text Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  16. 16
    The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable

    The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable Autor Thanyanan Reungwetwattana, Ying Liang, Viola W. Zhu, Sai‐Hong Ignatius Ou

    Vydáno 2016
    Získat plný text Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  17. 17
    Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC

    Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC Autor Shannon Zhang, Misako Nagasaka, Viola W. Zhu, Sai‐Hong Ignatius Ou

    Vydáno 2021
    Získat plný text Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  18. 18
    Targeting ROS1 with Anaplastic Lymphoma Kinase Inhibitors: A Promising Therapeutic Strategy for a Newly Defined Molecular Subset of Non–Small-Cell Lung Cancer

    Targeting ROS1 with Anaplastic Lymphoma Kinase Inhibitors: A Promising Therapeutic Strategy for a Newly Defined Molecular Subset of Non–Small-Cell Lung Cancer Autor Leow Pay Chin, Ross A. Soo, Richie Soong, Sai‐Hong Ignatius Ou

    Vydáno 2012
    Získat plný text Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  19. 19
    Asymptomatic Profound Sinus Bradycardia (Heart Rate ≤45) in Non-small Cell Lung Cancer Patients Treated with Crizotinib

    Asymptomatic Profound Sinus Bradycardia (Heart Rate ≤45) in Non-small Cell Lung Cancer Patients Treated with Crizotinib Autor Sai‐Hong Ignatius Ou, Michele C. Azada, Joni Dy, Jonathan A. Stiber

    Vydáno 2011
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  20. 20
    Alectinib Induces a Durable (&amp;gt;15 Months) Complete Response in an <i>ALK</i>-Positive Non-Small Cell Lung Cancer Patient Who Progressed on Crizotinib With Diffuse Leptomeningeal Carcinomatosis

    Alectinib Induces a Durable (&amp;gt;15 Months) Complete Response in an <i>ALK</i>-Positive Non-Small Cell Lung Cancer Patient Who Progressed on Crizotinib With Diffuse Leptomening... Autor Sai‐Hong Ignatius Ou, Karen R. Sommers, Michele C. Azada, Edward B. Garon

    Vydáno 2015
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:

Vyhledávací nástroje: